| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Nephrology | 74 / 88 | 16th | Q4 |
| Endocrinology, Diabetes and Metabolism | 216 / 250 | 13th | Q4 |
Compare journals
Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Journal of Parathyroid Disease
Journal of Parathyroid Disease is Scopus-indexed (Q4, CiteScore 0.6). Published by Nickan Research Institute.
Checked against the index lists dated .
ISSN 2345-6558Verify ISSN ↗
Publisher: Nickan Research Institute
Cost to publish: No APC data — check the publisher
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Quick answers
Is Journal of Parathyroid Disease indexed in Scopus?
Yes — actively indexed in Scopus, coverage 2020–present, best quartile Q4, CiteScore 0.6.
What quartile is Journal of Parathyroid Disease in Scopus?
Journal of Parathyroid Disease is Q4 in Nephrology (rank 74 of 88) and Q4 in Endocrinology, Diabetes and Metabolism (rank 216 of 250), by CiteScore 2025.
What is the impact factor of Journal of Parathyroid Disease?
Journal of Parathyroid Disease is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 0.6, quartile Q4, 16th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.118, quartile Q4, with an H-index of 3.
Who publishes Journal of Parathyroid Disease and what is its ISSN?
Journal of Parathyroid Disease is published by Nickan Research Institute. Its ISSN is 2345-6558.
Is Journal of Parathyroid Disease in Web of Science?
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Is Journal of Parathyroid Disease open access?
No — it is not registered as an open-access journal in DOAJ or Scopus.
How well cited is Journal of Parathyroid Disease? — open metrics via OpenAlex
Journal of Parathyroid Disease has an h-index of 10 and a 2-year mean of 0.34 citations per paper (OpenAlex). Its Scopus CiteScore is 0.6, quartile Q4. On 2-year citations it ranks #72 of 87 Scopus journals in Nephrology.
Journal of Parathyroid Disease published 18 papers in 2025; its busiest recent year was 2023 with 41. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
Who publishes in Journal of Parathyroid Disease? — latest 98 articles, 2021–2026
In its latest 98 research articles (2021–2026), authors are most often from Iran (70.9%), United States (5.4%) and Iraq (4.9%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Are there integrity warnings for Journal of Parathyroid Disease? — indicators, not proof of misconduct
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
- Scopus statusActive
- Retracted papers None recorded
- Problematic Paper Screener flags None flagged
- Author concentration70.9% of recent authorship from Iran
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Official sources & links
Community experience: reader comments on this journal
Related journals
8 journalsIndex data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.